Form 4: Kiniksa Pharmaceuticals Executive Awarded Performance-Based Share Units and Options

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, received performance share units and options tied to the progress of KPL-387, a treatment for recurrent pericarditis.

Summary

• Michael R. Megna, the Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, was granted performance share units (PSUs) and performance share options on May 1, 2025.
• The PSUs and options are contingent upon the achievement of specific performance criteria related to KPL-387, a treatment for recurrent pericarditis.
• A total of 6,703 PSUs were awarded, with 3,270 vesting upon submission of a biologics license application (BLA) to the FDA and 3,433 vesting upon FDA approval for commercial sale and marketing of KPL-387.
• Additionally, 10,741 performance share options were granted, with 5,285 vesting upon BLA submission and 5,456 vesting upon FDA approval.
• The vesting of these awards is also subject to Megna's continued employment with the company, with certain exceptions.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It describes standard executive compensation practices tied to the achievement of key milestones. The sentiment is driven by the potential for future value creation if the company successfully develops and commercializes KPL-387.

Positives

• The structure of the awards aligns executive compensation with the successful development and regulatory approval of KPL-387.
• The awards provide an incentive for the Chief Accounting Officer to contribute to the company's success in bringing KPL-387 to market.
• The vesting conditions are tied to clear, measurable milestones (FDA submission and approval), providing transparency and accountability.

Risks

• The vesting of the awards is contingent on FDA approval, which is subject to regulatory risk and uncertainty.
• Failure to achieve the performance criteria (FDA submission and approval) would result in the forfeiture of the awards.
• The value of the awards is subject to the market price of Kiniksa Pharmaceuticals' Class A Ordinary Shares, which can fluctuate.

Future Outlook

The future value of these awards is directly linked to the successful development, regulatory approval, and commercialization of KPL-387.

Industry Context

The use of performance-based equity compensation is a common practice in the pharmaceutical industry to align executive incentives with the achievement of key clinical and regulatory milestones.

Comparison to Industry Standards

• Many pharmaceutical companies use performance-based equity awards to incentivize executives to achieve specific clinical and regulatory milestones.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar compensation structures tied to drug development and approval.
• The specific terms and conditions of these awards (e.g., vesting criteria, performance targets) vary depending on the company and the specific drug development program.

Stakeholder Impact

• Shareholders: The awards align executive incentives with shareholder value creation through successful drug development.
• Employees: The awards may have a positive impact on employee morale by demonstrating the company's commitment to rewarding performance.
• Patients: Successful development of KPL-387 could provide a new treatment option for recurrent pericarditis.

Next Steps

• Kiniksa Pharmaceuticals will need to achieve the performance criteria (FDA submission and approval) for KPL-387 for the awards to vest.
• The Chief Accounting Officer will need to remain employed with the company to be eligible for vesting, subject to certain exceptions.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Performance Share Units, Performance Share Options, KPL-387, Recurrent Pericarditis, FDA Approval, Michael R. Megna, Executive Compensation, Vesting, Biologics License Application